Marktprognose für kardiometabolische Erkrankungen im Nahen Osten und in Afrika bis 2028 – Auswirkungen von COVID-19 und regionale Analyse nach Typ (Herz-Kreislauf-Erkrankung (CVD), Typ-2-Diabetes, Bluthochdruck und Fettleibigkeit), Behandlung (ACE-Hemmer, Diuretika, Glucophage und andere), Dosierung (Tablette und Injektion), Verabreichungsweg (oral und intravenös), Endbenutzer (Krankenhaus, Klinik und häusliche Pflege) und Vertriebskanal (Krankenhausapotheke, Einzelhandelsapotheke und Online-Apotheke)
Markteinführung
Die kardiometabolische Erkrankung ist durch eine Gruppe von Anomalien und Symptomen gekennzeichnet, die auftreten das Risiko, dass Personen eine Herz-Kreislauf-Erkrankung entwickeln. Zu den Symptomen gehören Bluthochdruck, Fettleibigkeit, Insulinresistenz, Dyslipidämie, schlechtes Cholesterinprofil (LDL) und Glukosetoleranz. Personen, die am kardiometabolischen Syndrom leiden, sind anfällig für mehrere andere lebensbedrohliche Krankheiten wie Typ-2-Diabetes, Schlaganfall, koronare Herzkrankheit (KHK), Herz-Kreislauf-Erkrankungen (CVD) und viele andere.
Darüber hinaus wird erwartet, dass die zunehmende Prävalenz kardiometabolischer Erkrankungen das Marktwachstum im Prognosezeitraum ankurbeln wird. Allerdings schränkt die Unterdiagnose von Herz-Kreislauf-Erkrankungen in Ländern mit niedrigem und mittlerem Einkommen (LMICs) das Wachstum des Marktes für kardiometabolische Erkrankungen im Nahen Osten und in Afrika ein.
Die Pandemie hat die Nachfrage erhöht medizinische Geräte, die in der häuslichen Pflege eingesetzt werden können. Die Region verzeichnet eine steigende Zahl von Patienten, die auf Intensivstationen (ICU) aufgenommen werden. Eine steigende Anzahl von Medikamenten stellt belastete Gesundheitssysteme vor vielfältige diagnostische und therapeutische Herausforderungen und führt zu einem Anstieg von Medizinprodukten und Arzneimitteln. Auch die Zahl chronischer Erkrankungen nimmt zu, was zu einem verstärkten Einsatz von Medikamenten zur Bekämpfung des Virus führt. Während der weit verbreiteten COVID-19-Pandemie gab es Bedenken hinsichtlich des Potenzials bestimmter Blutdruckmedikamente wie Angiotensin-Converting-Enzym-Hemmer (ACEi) und Angiotensin-Converting-Blocker (ARB). Das aktuelle schwere Coronavirus 2 mit akutem respiratorischem Syndrom (SARS-CoV-2) nutzt die membrangebundenen Angiotensin-Converting-Enzym-2-Rezeptoren (ACE2), um den Eintritt in die Wirtszelle zu erleichtern. Diese Pandemie verbesserte die Geschäftstätigkeit der verschiedenen Arzneimittelhersteller, die in der Region auf dem Markt für Herz-Kreislauf-Erkrankungen tätig sind.
Marktüberblick und -dynamik
Der Markt für kardiometabolische Erkrankungen im Nahen Osten und Afrika wird bis 2028 voraussichtlich 5.008,5 Millionen US-Dollar erreichen, gegenüber 4.300,9 Millionen US-Dollar im Jahr 2021; Von 2021 bis 2028 wird ein durchschnittliches jährliches Wachstum von 2,2 % erwartet. Die CMD-basierte Arzneimittelkandidaten-Pipeline wird für ein breites Spektrum therapeutischer Anwendungen, darunter Bluthochdruck, Diabetes und entzündliche Erkrankungen, erweitert. Viele große und kleine Pharmaunternehmen sind an der Entwicklung verschiedener niedermolekularer Medikamente beteiligt. Beispielsweise verfügt AstraZeneca über mehr als 25 Therapien und Therapiekombinationen in den Bereichen Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen im frühen bis späten Stadium (CVRM). Basierend auf fortschrittlichen Technologien werden mehrere Produkte zur Behandlung von CMDs eingeführt. Darüber hinaus treiben die zunehmenden Investitionen in die CMD-Forschung den Markt für kardiometabolische Erkrankungen erheblich voran. All diese Investitionen wirken sich positiv auf das Wachstum dieses Marktes für Herz-Kreislauf-Erkrankungen im Nahen Osten und in Afrika aus.
Wichtige Marktsegmente
In Bezug auf die Art hatte das Segment der Herz-Kreislauf-Erkrankungen im Jahr 2020 den größten Anteil am Markt für kardiometabolische Erkrankungen im Nahen Osten und in Afrika. In Bezug auf die Behandlung entfiel der Anteil auf das Segment der ACE-Hemmer für den größten Anteil am Markt für Herz-Kreislauf-Erkrankungen im Nahen Osten und in Afrika im Jahr 2020. In Bezug auf die Dosierung hatte das Tablettensegment im Jahr 2020 den größten Anteil am Markt für Herz-Kreislauf-Erkrankungen im Nahen Osten und in Afrika Das Segment hatte im Jahr 2020 den größten Anteil am Markt für Herz-Kreislauf-Erkrankungen im Nahen Osten und in Afrika. In Bezug auf den Endverbraucher hatte das Krankenhaussegment im Jahr 2020 den größten Anteil am Markt für Herz-Kreislauf-Erkrankungen im Nahen Osten und in Afrika. Darüber hinaus basierend auf dem Vertriebskanal , das Segment für Krankenhausapotheken hatte im Jahr 2020 den größten Marktanteil.
Wichtige Quellen und Unternehmen gelistet
Einige wichtige primäre und sekundäre Quellen, auf die bei der Erstellung dieses Berichts über den Markt für kardiometabolische Erkrankungen im Nahen Osten und in Afrika Bezug genommen wird, sind Unternehmenswebsites, Jahresberichte, Finanzberichte, unter anderem nationale Regierungsdokumente und statistische Datenbanken. Zu den wichtigsten im Bericht aufgeführten Unternehmen gehören Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S und AstraZeneca.
Bericht über Kaufgründe
- Um den Markt für kardiometabolische Erkrankungen im Nahen Osten und in Afrika zu verstehen Marktlandschaft und identifizieren Sie Marktsegmente, die wahrscheinlich eine hohe Rendite garantieren
- Um die sich ständig verändernde Marktlandschaft zu verstehen und im Wettbewerb die Nase vorn zu haben
- Um Fusionen und Übernahmen sowie Partnerschaftsabkommen im Markt für Herz-Kreislauf-Erkrankungen im Nahen Osten und in Afrika effizient zu planen, indem Segmente mit den vielversprechendsten wahrscheinlichen Verkäufen identifiziert werden.
- Um sachkundige Geschäfte zu machen Entscheidungen aus einer einfühlsamen und umfassenden Analyse der Marktleistung verschiedener Segmente
- Um eine Marktumsatzprognose für den Markt für Herz-Kreislauf-Erkrankungen im Nahen Osten und in Afrika auf der Grundlage verschiedener Segmente zu erhalten Zeitraum 2021–2028
MARKTSEGMENTIERUNG FÜR KARDIOMETABOLISCHE ERKRANKUNGEN IM MITTLEREN OSTEN UND AFRIKA
< p>Nach Typ- Herz-Kreislauf-Erkrankung (CVD)
- Typ-2-Diabetes
- Bluthochdruck
- Fettleibigkeit
< span>Durch Behandlung
- ACE-Hemmer
- Diuretika
- Glucophage
- Andere
Nach Dosierung
- Tablette
- Injektion
- Oral
- Intravenös
Von Endbenutzern
- Krankenhaus
- Klinik
- Homecare-Einstellungen
Von Vertriebskanal
- Krankenhausapotheke
- Einzelhandelsapotheke
- Online-Apotheke
Nach Land
- Naher Osten und Afrika
- VAE
- Saudi-Arabien
- Südafrika
- Restlicher Naher Osten und Afrika
Erwähnte Unternehmen
- Bayer AG
- Novartis AG ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Middle East and Africa Cardiometabolic Diseases market – By Country
2. Middle East and Africa Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East and Africa Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Middle East and Africa Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Middle East and Africa Cardiometabolic Diseases Market – Regional Analysis
6.1 Middle East and Africa Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Middle East and Africa Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Middle East and Africa Cardiometabolic Diseases Market – Geographic Analysis
13.1 Middle East and Africa: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 Middle East & Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.1.3 Middle East & Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 Middle East & Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 Middle East & Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 Middle East & Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 Middle East & Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 Middle East & Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.9.1.1 Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.10 Saudi Arabia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 Saudi Arabia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 Saudi Arabia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 Saudi Arabia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 Saudi Arabia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 Saudi Arabia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.15.1.1 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.15.1.2 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.16 UAE: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 UAE: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 UAE: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 UAE: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 UAE: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 UAE: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.21.1.1 South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.22 South Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 South Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 South Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 South Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 South Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 South Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.27.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.27.1.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.28 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.29 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.30 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.31 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.32 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.33 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market
14.1 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
15. Middle East and Africa Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Bayer AG
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Novartis AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Boehringer Ingelheim International GmbH
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novo Nordisk A/S
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 AstraZeneca
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Middle East & Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. Middle East & Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Middle East & Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. Middle East & Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. Middle East & Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. Saudi Arabia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Saudi Arabia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. Saudi Arabia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Saudi Arabia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. Saudi Arabia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. Saudi Arabia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. UAE Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. UAE Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. UAE Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. UAE Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. UAE Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. UAE Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. South Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. South Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. South Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. South Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. South Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. South Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 27. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 29. Rest of Middle East and Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 30. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 31. Organic Developments in the Cardiometabolic Diseases Market
Table 32. Inorganic Developments in the Cardiometabolic Diseases Market
Table 33. Glossary of Terms, Middle East and Africa Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Middle East and Africa Cardiometabolic Diseases Market Segmentation
Figure 2. Middle East and Africa Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Middle East and Africa Cardiometabolic Diseases Market
Figure 4. Middle East and Africa Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Middle East and Africa Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Middle East and Africa PEST Analysis
Figure 7. Middle East and Africa Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Middle East and Africa Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Middle East and Africa: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. Middle East & Africa Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Million)
Figure 35. Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market
Figure 41. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East and Africa cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East and Africa cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.